Acting today, designing for tomorrow’s health

Our Specialties

We’re building upon strong legacies of medical innovation to develop and deliver breakthrough therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems.  

We work each day to live our core mission: providing solutions that extend and enhance life for patients who experience our treatment solutions.

Learn more about our specialties in Cardiac Surgery, Neuromodulation, along with our Strategic Portfolio Initiatives.

  • Cardiopulmonary global leader
    • #1 in Heart-lung machines
    • #1 in Oxygenators
  • Leading player in mechanical and tissue valves
  • Offering Advanced Temporary Cardiopulmonary Support Solutions, including ExtraCorporeal Life Support (ECLS) and Percutaneous Mechanical Circulatory Support (pMCS)
  • On-going roll out of new products
  • Long-standing leader in Neuromodulation
  • #1 position in implantable devices for epilepsy
    • FDA approval for SenTiva®
  • Neurostimulation for the treatment of obstructive sleep apnea (OSA) via implantable device
    • CE Mark approval
    • FDA pivotal study enrollment underway
  • Treatment-Resistant Depression (TRD)
    • FDA and CE Mark approvals for VNS Therapy treatment
  • Transcatheter Mitral Valve Replacement (TMVR)
  • Heart Failure
    • CE Mark for VITARIA™ VNS Therapy treatment

Cardiac Surgery

As a global leader in cardiac surgery, our advanced solutions have made significant contributions to open-heart surgery outcomes for many patients.

Our devices and systems are used in more than 50% of open-heart surgery procedures worldwide.
The work doesn’t stop there. Our global R&D centers are powered by scientists driven to find smarter and more affordable solutions to treat heart conditions.

Through our commitment to continuous training and education, we’re responsive to the needs of patients, physicians, hospitals, and healthcare stakeholders.   

Learn more about our Cardiac Surgery business.

Learn more about our Advanced Temporary Cardiopulmonary Support Solutions.

Updates on the 3T Heater-Cooler device -- Outside the U.S. or U.S.



We strive to advance patient care through insightful application of innovative technologies.

As pioneers of the VNS (Vagus Nerve Stimulation) Therapy® system, we continue to advance medical device solutions for people affected by treatment-resistant epilepsy, depression, heart failure and other chronic disorders.  

We treat obstructive sleep apnea (OSA) with an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, opening the airway while a patient is sleeping.

We collaborate with top researchers, partners, and experienced clinicians to enhance solutions, improve patient outcomes, and achieve physician satisfaction by providing safe and effective treatment options that positively impact quality of life.  

Learn more about our VNS Therapy System.

Learn more about our OSA device.

Manuals for Healthcare Providers:


Strategic Portfolio Initiatives

Our product portfolio has multiple strategic portfolio initiatives (SPIs), which are mid- to long-term growth drivers for the company. These SPIs include:

  • VNS Therapy for Treatment-Resistant Depression (TRD) – Depression is the leading cause of disability worldwide, and VNS Therapy may provide better outcomes and symptom improvement for patients with TRD.
  • Transcatheter Mitral Valve Replacement (TMVR) – Nearly 1 in 10 people age 75 or older has moderate to severe Mitral Regurgitation.1,2 LivaNova is conducting a clinical trial for the Caisson TMVR, which uses a tube (catheter) through an incision in the groin instead of open-heart surgery to replace the mitral valve.
  • VITARIA™ for Heart Failure – The leading cause of morbidity and mortality is Heart Failure. Using its VNS Therapy System, LivaNova’s novel delivery of Autonomic Regulation Therapy (ART) may improve regulation of cardiovascular function.


1. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.

2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011.